Octagam® 10%

The First and Only FDA-Approved IVIg Therapy
for Dermatomyositis in Adults

Newly Approved Indication!

The U.S. Food and Drug Administration (FDA) has approved octagam 10% [Immune Globulin Intravenous (Human)] for the treatment of dermatomyositis (DM) in adults1, a rare, immune-mediated inflammatory disease.

FDA approval for the new indication was based on the results of ProDERM, a pivotal randomized clinical trial and the first to evaluate the long-term efficacy and safety of IVIg therapy for adults with DM.

Learn More

If you'd like to talk to an Octapharma Medical Science Liaison or your local Sales Representative about octagam 10% and stay current on product updates, just complete and submit the form.

Keep Me Updated on Octagam

*Required fields

By submitting this form, you are consenting to receive future communications from Octapharma and/or an Octapharma representative. Please review our Privacy Policy.

References:

  1. Octagam 10% Full Prescribing Information. Paramus, NJ: Octapharma USA Inc; rev June 2021
GAM10-0239
Indications and Important Safety Information for octagam® 10% [Immune Globulin Intravenous (Human) 10% Liquid Preparation]
WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
Please see octagam 10% full Prescribing Information for complete boxed warning and other important information.